Next Article in Journal
Human Dendritic Cells: Ontogeny and Their Subsets in Health and Disease
Next Article in Special Issue
Transglutaminase 2 Up-Regulation Is Associated with Inflammatory Response in PBMC from Healthy Subjects with Hypovitaminosis D
Previous Article in Journal
Microbiota and Phage Therapy: Future Challenges in Medicine
Previous Article in Special Issue
Role of Transglutaminase 2 in Migration of Tumor Cells and How Mouse Models Fit
Open AccessReview

New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds

Tumor Microenvironment Research Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Korea
Med. Sci. 2018, 6(4), 87;
Received: 19 September 2018 / Revised: 28 September 2018 / Accepted: 5 October 2018 / Published: 8 October 2018
(This article belongs to the Special Issue Transglutaminases in Health and Disease)
Transglutaminase 2 (EC; TG2 or TGase 2) plays important roles in the pathogenesis of many diseases, including cancers, neurodegeneration, and inflammatory disorders. Under normal conditions, however, mice lacking TGase 2 exhibit no obvious abnormal phenotype. TGase 2 expression is induced by chemical, physical, and viral stresses through tissue-protective signaling pathways. After stress dissipates, expression is normalized by feedback mechanisms. Dysregulation of TGase 2 expression under pathologic conditions, however, can potentiate pathogenesis and aggravate disease severity. Consistent with this, TGase 2 knockout mice exhibit reversal of disease phenotypes in neurodegenerative and chronic inflammatory disease models. Accordingly, TGase 2 is considered to be a potential therapeutic target. Based on structure–activity relationship assays performed over the past few decades, TGase 2 inhibitors have been developed that target the enzyme’s active site, but clinically applicable inhibitors are not yet available. The recently described the small molecule GK921, which lacks a group that can react with the active site of TGase 2, and efficiently inhibits the enzyme’s activity. Mechanistic studies revealed that GK921 binds at an allosteric binding site in the N-terminus of TGase 2 (amino acids (a.a.) 81–116), triggering a conformational change that inactivates the enzyme. Because the binding site of GK921 overlaps with the p53-binding site of TGase 2, the drug induces apoptosis in renal cell carcinoma by stabilizing p53. In this review, we discuss the possibility of developing TGase 2 inhibitors that target the allosteric binding site of TGase 2. View Full-Text
Keywords: transglutaminase 2; inhibitor; conformation; dimer; polymerization; cross-linking transglutaminase 2; inhibitor; conformation; dimer; polymerization; cross-linking
Show Figures

Figure 1

MDPI and ACS Style

Kim, S.-Y. New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds. Med. Sci. 2018, 6, 87.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop